Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2013 Sep 14;72(5):10.1007/s00280-013-2283-x. doi: 10.1007/s00280-013-2283-x

Fig 2.

Fig 2

Intra-individual changes of nilotinib AUC (A), Cmax (B), Tmax (C), and half-life (D) when p.o. nilotinib was co-administered with calcium carbonate to healthy volunteers.